ストックスクリーナーアプリを入手
1.22
7.96%
0.09
前日終値:
$1.13
開ける：
$1.14
24時間の取引高:
1.93M
Relative Volume:
1.76
時価総額：
$86.26M
収益：
-
当期純損益:
$-95.71M
株価収益率:
-0.5101
EPS:
-2.3915
ネットキャッシュフロー:
$-87.27M
1週間 パフォーマンス:
+4.27%
1か月 パフォーマンス:
-13.48%
6か月 パフォーマンス:
-40.49%
1年 パフォーマンス:
-54.65%
1日の値動き範囲:
$1.14
$1.265
1週間の範囲:
$1.07
$1.265
52週間の値動き範囲:
$0.8719
$3.08
Biomea Fusion Inc Stock (BMEA) Company Profile
Compare BMEA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.22 | 79.90M | 0 | -95.71M | -87.27M | -2.3915 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | 開始されました | Rodman & Renshaw | Buy |
| 2025-08-28 | 開始されました | Jefferies | Buy |
| 2025-06-03 | 再開されました | Piper Sandler | Overweight |
| 2024-10-09 | 開始されました | Edward Jones | Buy |
| 2024-09-27 | アップグレード | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | アップグレード | Truist | Hold → Buy |
| 2024-08-29 | 開始されました | CapitalOne | Overweight |
| 2024-06-11 | ダウングレード | Truist | Buy → Hold |
| 2024-06-07 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-04-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 開始されました | Truist | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-06-26 | ダウングレード | Jefferies | Buy → Hold |
| 2023-05-12 | 開始されました | Barclays | Overweight |
| 2023-03-29 | 繰り返されました | Oppenheimer | Outperform |
| 2023-03-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-02-24 | 開始されました | Citigroup | Buy |
| 2022-06-02 | 再開されました | H.C. Wainwright | Buy |
| 2022-01-12 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-17 | 開始されました | Oppenheimer | Outperform |
| 2021-05-11 | 開始されました | JP Morgan | Overweight |
| 2021-05-11 | 開始されました | Jefferies | Buy |
| 2021-05-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Biomea Fusion Inc (BMEA) 最新ニュース
Biomea Fusion Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Insider Monkey
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Biomea Fusion 2025 Financial Report - AlphaStreet
Aug Shorts: Can Biomea Fusion Inc ride the EV wave2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Biomea Fusion, Inc. 2025 Annual Report: Advancing Oral Diabetes & Obesity Therapies with Innovative Small Molecule Drugs - Minichart
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - Bitget
Biomea Fusion (NASDAQ:BMEA) Issues Quarterly Earnings Results - MarketBeat
Biomea 10-K: $0 Revenue, $(1.18) EPS; net loss narrows to $(61.80)M - TradingView
BMEA: Clinical progress in diabetes and obesity, reduced net loss, and strong cash position into 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) highlights icovamenib Phase II data - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Biomea Fusion (BMEA) cuts 2025 loss as icovamenib and GLP‑1 obesity programs advance - Stock Titan
Biomea lines up four diabetes and obesity readouts before cash runs out - Stock Titan
Biomea Fusion targets new partnerships and investor interest at BIOEurope2026 - Traders Union
Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
If You Invested $1,000 in Biomea Fusion, Inc. (BMEA) - Stock Titan
BMEA SEC FilingsBiomea Fusion, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Street Watch: Is Biomea Fusion Inc stock overvalued or fairly priced2026 Closing Moves & Verified Momentum Stock Watchlist - baoquankhu1.vn
Heights Capital Management Inc. Reduces Stock Holdings in Biomea Fusion, Inc. $BMEA - MarketBeat
Why Is Biomea Fusion (BMEA) Stock Down 63% Today? - TradingView
Biomea Fusion, Inc. (BMEA) Presents at 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026Slideshow (NASDAQ:BMEA) 2026-03-16 - Seeking Alpha
Biomea Fusion Presents Positive Phase II COVALENT-111 Data in Type 2 Diabetes - National Today
Juan Pablo Frias presents diabetes research for Biomea Fusion at ATTD 2026 - Traders Union
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib - Benzinga
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - The Manila Times
Biomea Fusion Reports Positive 52-Week Results for Icovamenib in Type 2 Diabetes at ATTD 2026 Conference - Quiver Quantitative
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 - GlobeNewswire
D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - MSN
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027 - MarketBeat
Biomea Fusion, Inc. (BMEA) Presents at The Citizens Life Sciences Conference 2026Slideshow - Seeking Alpha
Aug Fed Impact: Can Biomea Fusion Inc sustain its profitabilityMarket Movers & Risk Managed Investment Entry Signals - baoquankhu1.vn
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biomea Fusion to present icovamenib clinical data at ATTD 2006 - Traders Union
Biomea Fusion : Presentation Citizens Life Sciences Conference March 2026 - marketscreener.com
Icovamenib advances drive optimism for diabetes cure, Biomea Fusion asserts - Traders Union
Biomea Fusion (BMEA) Price Target Decreased by 10.64% to 7.14 - MSN
BMEA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Biomea Fusion, Inc. (BMEA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
Aug Spikes: Can Biomea Fusion Inc ride the EV waveWeekly Profit Analysis & Real-Time Stock Entry Alerts - baoquankhu1.vn
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf. - MarketBeat
BMEA: Icovamenib and BMF-650 advance in trials, targeting unmet needs in diabetes and weight loss - TradingView
Biomea Fusion : 1ST QUARTER 2026 Corporate Presentation OPCO - marketscreener.com
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline - TipRanks
Biomea Fusion posts updated investor presentation, confirms Phase II readouts and Phase I obesity data timing - TradingView
Biomea Fusion (NASDAQ: BMEA) details icovamenib and BMF-650 trial milestones - Stock Titan
Does Biomea Fusion Inc. stock trade at a discount to peersOptions Play & Momentum Based Trading Signals - mfd.ru
Biomea Fusion to Participate at Upcoming Investor Conferences - Investing News Network
Biomea Fusion advances metabolic disease science with visionary approach - Traders Union
7.85M Biomea Fusion (BMEA) shares reported in 9.9% ownership filing - Stock Titan
Biomea Fusion Inc (BMEA) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):